Sanderson J E, Chan W W, Hung Y T, Chan S K, Shum I O, Raymond K, Woo K S
Department of Medicine, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong.
Br Heart J. 1995 Nov;74(5):502-7. doi: 10.1136/hrt.74.5.502.
This study examines the acute effects of two differing beta adrenergic blocking agents (metoprolol and a third generation vasodilating beta blocker) on plasma concentrations of atrial natriuretic factor (ANF), brain (ventricular) natriuretic factor (BNF), and haemodynamic variables in patients with heart failure.
University teaching hospital.
20 patients with impaired left ventricular systolic function [ejection fraction 32 (SEM 2.3)%] were randomised in a double blind manner to receive either oral metoprolol 6.25 mg twice daily or celiprolol 25 mg daily. Haemodynamic variables were evaluated by Swan-Ganz pulmonary artery catheter over 24 hours. ANF and BNF concentrations were measured at baseline, 5 h, and 24 h by radioimmunoassay.
At baseline ANF and BNF concentrations were considerably raised compared to the normal range. Treatment with metoprolol caused ANF to rise further to 147% of the basal level at 5 h (P = 0.017) and 112% at 24 h (P = 0.029). This was associated with a small but non-significant rise in pulmonary capillary wedge pressure. Cardiac output and systemic vascular resistance were unchanged at 24 h. In contrast, after celiprolol ANF fell to 90% of basal levels at 5 h and to 74% of basal level at 24 h (P = 0.019), associated with a small but non-significant fall in pulmonary capillary wedge pressure [-3.3 (2.7) mm Hg] and systemic vascular resistance, and rise in cardiac output from 3.2 (0.2) to 4.0 (0.4) l/min (P = 0.04). BNF concentrations rose to 112% of baseline at 5 h (P = 0.09) after metoprolol but fell slightly, to 91% of baseline values, after celiprolol (NS).
Metoprolol, even in very low doses (6.25 mg), produced a rise in ANF and BNF, although minimal haemodynamic changes were detected. In contrast, a vasodilating beta blocker was associated with a significant fall in ANF and BNF and a small rise in cardiac output. This study confirms both the advantages of vasodilating beta blockers over metoprolol for initial treatment of heart failure and the usefulness of ANF and BNF measurements for the assessment of drug effects in heart failure compared to traditional haemodynamic measurements.
本研究探讨两种不同的β肾上腺素能阻滞剂(美托洛尔和第三代血管舒张性β阻滞剂)对心力衰竭患者血浆心房利钠因子(ANF)、脑(心室)利钠因子(BNF)浓度及血流动力学变量的急性影响。
大学教学医院。
20例左心室收缩功能受损[射血分数32(标准误2.3)%]的患者以双盲方式随机分组,分别每日两次口服6.25mg美托洛尔或每日口服25mg塞利洛尔。通过Swan-Ganz肺动脉导管在24小时内评估血流动力学变量。在基线、5小时和24小时通过放射免疫分析法测量ANF和BNF浓度。
与正常范围相比,基线时ANF和BNF浓度显著升高。美托洛尔治疗使ANF在5小时时进一步升至基础水平的147%(P = 0.017),在24小时时升至112%(P = 0.029)。这与肺毛细血管楔压的小幅但无统计学意义的升高相关。24小时时心输出量和全身血管阻力未改变。相比之下,塞利洛尔治疗后,ANF在5小时时降至基础水平的90%,在24小时时降至基础水平的74%(P = 0.019),同时肺毛细血管楔压[-3.3(2.7)mmHg]和全身血管阻力小幅下降但无统计学意义,心输出量从3.2(0.2)升/分钟升至4.0(0.4)升/分钟(P = 0.04)。美托洛尔治疗后BNF浓度在5小时时升至基线的112%(P = 0.09),而塞利洛尔治疗后BNF浓度略有下降,降至基线值的91%(无统计学意义)。
美托洛尔即使剂量很低(6.25mg),也会使ANF和BNF升高,尽管检测到的血流动力学变化极小。相比之下,血管舒张性β阻滞剂与ANF和BNF的显著下降以及心输出量的小幅增加相关。本研究证实了血管舒张性β阻滞剂在心力衰竭初始治疗中优于美托洛尔的优势,以及与传统血流动力学测量相比,ANF和BNF测量在评估心力衰竭药物疗效方面的有用性。